Dimeric Antigen Receptors
AssigneeSorrento Therapeutics, Inc.
InventorsHenry Hongjun Ji, Wenzhong Guo, Yanliang Zhang, Gunnar F. Kaufmann, Bei Bei Ding
Life of this patent
Estimating the term…
Abstract
The present disclosure provides dimeric antigen receptors (DAR) constructs comprising a heavy chain binding region on one polypeptide chain and a light chain binding region on a separate polypeptide chain. The two polypeptide chains that make up the dimeric antigen receptors can dimerize to form an antigen binding domain. The dimeric antigen receptors have antibody-like properties as they bind specifically to a target antigen. The dimeric antigen receptors can be used for directed cell therapy.
Claims20
A dimeric antigen receptor (DAR) construct comprising:
- an antigen binding domain comprising a first and second polypeptide chain, wherein
- a) the first polypeptide chain comprises five regions ordered from the amino terminus to the carboxyl terminus:
- (i) an antibody heavy chain variable region (VH), (ii) an antibody heavy chain constant region (CH), (iii) a hinge region or no hinge region, (iv) a transmembrane region (TM), and (v) an intracellular signaling region;
- and
- b) the second polypeptide chain comprises two regions ordered from the amino terminus to the carboxyl terminus:
- (i) an antibody light chain variable region (VL) (e.g., kappa or lambda), and (ii) an antibody light chain constant region (CL).
A precursor polypeptides comprising ten regions ordered from the amino terminus to the carboxyl terminus:
- (1) a heavy chain leader sequence (2) an antibody heavy chain variable region, (3) an antibody heavy chain constant region, (4) an optional hinge region, (5) a transmembrane region, (6) an intracellular signaling region, (7) a T2A cleavage sequence, (8) a light chain leader sequence, (9) an antibody light chain variable region, and (10) an antibody light chain constant region.
Dependencies are inferred from the claim text.